July 8, 2025 4:29pm
Uncertainty around tariffs didn’t stop cell and gene therapy sector share pricing’s rally; the problem with algos and electronic trading is usually depreciation and then appreciation with/post them
However today, President Trump has threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon”; saying tariffs will incentivize drug companies to move manufacturing operations to the U.S. – agreed!
I say what others won’t, so you can do what others can’t!
I also try to answer as many whys, as I can while providing the metrics to validate my thesis
Never leave an investor uninformed!
On point, short on words, long on facts and being judicious!
My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.
I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key sector-moving events and distill that into a cogent outlook.
RegMed Investors’ (RMi) pre-open: “uncle algo” withdraws upside from share pricing, my thoughts, some recover … https://www.regmedinvestors.com/articles/13987
Monday night’s RegMed Investors (RMi) Closing Bell: Staring into the abyss … https://www.regmedinvestors.com/articles/13986
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812
Tuesday: The Dow closed DOWN -165.60 points or -0.37%, the S&P closed DOWN -4.46 points or -0.07% while the Nasdaq closed UP +5.95 points or +0.03%
- Theme of the session, conflicting signals from Trump on trade waits for further clarity
- The upside responds after the pillage of cell and gene therapy sector’s share pricing by algos and electronic trading
Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy
- The National Federation of Independent Business Small Business Optimism Index dipped to 98.6 in June vs. the 98.7 estimate. It also lagged May's 98.8 reading.
Tuesday’s advance/decline line opened positive with 23 incliners, 10 decliners and 2 flats ending with a positive close of 22 incliners, 10 decliners and 3 flats
Metrics: Tuesday, the IBB was up +1.21%, the XBI was up +1.07% while the VIX was down -0.97 points or -5.45% at 16.82
Q3 – 7/1/25 – 1 market holiday, 4 positive and 1 negative closes
Q2/25:
- June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
- May – 1 market holiday, 10 negative and 11 positive closes
- April – 11 positive and 10 negative closes
Tuesday Closing UP (10 of 22) +$ after Monday’s
- CRISPR Therapeutics (CRSP +$3.62 after Monday’s -$0.98
- Moderna (MRNA +$2.64 after Monday’s -0.31)
- Beam Therapeutics (BEAM +$1.11 after Monday’s -$0.83),
- Intellia Therapeutics (NTLA +$0.87 after Monday’s -$0.49),
- Vericel (VCEL +$0.76 after Monday’s -$2.33),
- BioLife Solutions (BLFS +$0.74 after Monday’s -$1.03),
- MiMedx (MDXG +$0.52 after Monday’s +$0.15),
- Solid Biosciences (SLDB +$0.33),
- Editas Medicine (EDIT +$0.31),
Flat (3)
- bluebird bio (BLUE) P/E acquired
- Blueprint Medicine (BPMC $0.00 after Monday’s+$0.05)
- Homology Medicine (FIXX)
Tuesday’s Closing DOWN (10 of 10): -$ after Monday’s
- Alnylam Pharmaceuticals (ALNY -$6.63 after Monday’s -$7.78),
- Ionis Pharmaceuticals (IONS -$0.46 after Monday’s -$1.22)
- Agenus (AGEN -$0.32 after Monday’s -$0.89),
- Ultragenyx Pharmaceuticals (RARE -$0.19),
- Harvard Apparatus RT (OTCQB: HRGN -$0.14 after Monday’s $0.00),
- Lenz Therapeutics (LENZ -$0.12 after Monday’s -$1.11),
- Mesoblast (MESO -$0.08),
- Verve Therapeutics (VERV -$0.03),
- Sage Therapeutics (SAGE -$0.01),
- Sangamo Therapeutics (SGMO -$0.0015),
The BOTTOM LINE: Lower yields on U.S. Treasury debt have proven the latest fuel for a “melt-up in risk assets,” and the looming tariff deadlines are “unlikely to matter much,” before President Trump released letters announcing sharp tariffs on Japan, South Korea and others starting in August. < HSBC chief multi-asset strategist Max Kettner wrote to clients on Monday> …
- Melt-up ingredients range from “the big beautiful bill, some U.S. trade deals (e.g. Vietnam, potentially), a U.S. labor market that’s been defying the doom-and-gloom calls — not only last month but in the entire second quarter” to lower Treasury yields that are “still being far away from the Danger Zone.” <CNBC>
Volume was slightly lower on the Nasdaq exchange and higher on the NYSE compared with Monday. Advancers beat decliners by more than 9-to-5 on both exchanges
Cell and gene therapy sector equities on Tuesday shot to the upside after diving on Monday ….
- After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.
As I also wrote, about June… Some believe in a “June Swoon;” … however, July will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”
- There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.
Last session of June as July evolves ‘25: understand the “flow” …
- 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
- 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats
- 7/4 – Friday market holiday
- 7/3 – Thursday closed positive with 23 positive, 6 negative and 6 flats
- 7/2 - Wednesday closed positive with 24 positive, 7 negative and 4 flats
- 7/1 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
- If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
Why do I keep repeating, so investors can make the connection …
The top three (3) performing in the session:
- Tuesday: CRISPR Therapeutics (CRSP), Moderna (MRNA) and Beam Therapeutics (BEAM)
- Monday: Prime Medicine (PRME), AxoGen (AXGN) and MiMedx (MDXG)
- Friday was a market holiday
- Thursday: Alnylam Pharmaceuticals (ALNY), Lenz Therapeutics (LENZ) and Agenus (AGEN)
The worst three (3) in the session:
- Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Agenus (AGEN)
- Monday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Lenz Therapeutics (LENZ)
- Friday was a market holiday
- Thursday: Ionis Pharmaceuticals (IONS), Mesoblast (MESO) and AxoGen (AXGN)
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.
I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
